Skip to main content

Table 1 Population characteristics. Data are expressed as n (%) or median (IQR)

From: Crohn’s disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic

  CD n = 21 UC n = 56
Gender (F) 13 (61.9%) 33 (58.9)
Age 59.1 (45.2–65.8) 56.3 (40.3–64.1)
Disease duration 6 (5–10) 7 (3–12)
Extent
 E1(proctitis and proctosigmoiditis)   8 (14.3%)
 E2(left sided colitis)   29 (51.8%)
 E3 (pancolitis)   17 (33.9%)
Localization
 L1 (ileal) 13 (61.9%)  
 L2 (colic) 3 (14.3%)  
 L3 (ileocolic) 5 (23.8%)  
Behavior
 B1 (inflammatory) 12 (57.1%)  
 B2 (stenotizing) 6 (28.6%)  
 B3 (penetrating) 3 (14.3%)  
 Biologics/ISS 9 (42.7%) 4 (7.14%)
 Surgery 6 (28.6%) 0 (0%)